GO
Loading...

Pfizer Inc

More

  • NEW YORK, July 28- Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.

  • Final Glance: Pharmaceuticals companies Thursday, 24 Jul 2014 | 6:22 PM ET

    Baxter International Inc. rose$. 16 or. 2 percent, to $77.00. Bristol-Myers Squibb Co. rose$. 14 or. 3 percent, to $49.46. Hospira rose $1.16 or 2.3 percent, to $51.82.

  • At least eight European law firms are pitching their services to major U.S. law firms and Wall Street banks, hoping that U.S. companies considering an inversion choose Ireland, Britain or the Netherlands for their new tax domicile, according to people with knowledge of the matter.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • Midday Glance: Pharmaceuticals companies Thursday, 24 Jul 2014 | 1:23 PM ET

    Baxter International Inc. rose$. 20 or. 3 percent, to $77.04. Bristol-Myers Squibb Co. rose$. 20 or. 4 percent, to $49.52. Hospira rose$. 74 or 1.5 percent, to $51.40.

  • Early Glance: Pharmaceuticals companies Thursday, 24 Jul 2014 | 11:37 AM ET

    Baxter International Inc. fell$. 13 or. 2 percent, to $76.71. Bristol-Myers Squibb Co. fell$. 16 or. 3 percent, to $49.16. Hospira rose$. 03 or. 1 percent, to $50.69.

  • July 24- Eli Lilly and Co's quarterly revenue plunged due to generic competition for its Cymbalta depression drug and its Evista osteoporosis treatment, but cost controls helped earnings beat forecasts.

  • Bristol 2Q net drops on lower drug sales, charges Thursday, 24 Jul 2014 | 7:42 AM ET

    NEW YORK— Bristol-Myers Squibb Co.' s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.

  • Obama wants limits on US company mergers abroad Thursday, 24 Jul 2014 | 3:03 AM ET

    LOS ANGELES— Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers. "I don't care if it's legal," Obama declared.

  • U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.

  • This stock soared 300%, but options smell 'fishy' Wednesday, 23 Jul 2014 | 9:45 AM ET

    Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.

  • July 22- Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.

  • Final Glance: Pharmaceuticals companies Tuesday, 22 Jul 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 76 or 1.0 percent, to $76.87. Bristol-Myers Squibb Co. rose$. 20 or. 4 percent, to $49.12. Hospira rose$. 31 or. 6 percent, to $50.78.

  • Midday Glance: Pharmaceuticals companies Tuesday, 22 Jul 2014 | 1:57 PM ET

    Baxter International Inc. rose$. 93 or 1.2 percent, to $77.04. Bristol-Myers Squibb Co. rose$. 41 or. 8 percent, to $49.33. Hospira rose$. 27 or. 5 percent, to $50.74.

  • Dems press blocks on corporate tax inversions plans Tuesday, 22 Jul 2014 | 8:35 AM ET

    Democrats, searching for campaign issues before November's congressional elections, have jumped on inversions, and several of them have offered bills that would curb the deals.

  • Early Glance: Pharmaceuticals companies Monday, 21 Jul 2014 | 11:37 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $76.15. Bristol-Myers Squibb Co. fell$. 28 or. 6 percent, to $48.84. Hospira fell$. 06 or. 1 percent, to $50.09.

  • July 18- Catalent Inc, controlled by Blackstone Group LP, said it expects its initial public offering to be priced between $19 and $22 per share, valuing the company at about $2.57 billion at the top end. The company's major customers include Pfizer Inc, Johnson& Johnson, GlaxoSmithKline Plc, Merck& Co Inc and Novartis AG.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.

  • July 17- Shire Plc and U.S. drugmaker Abbvie Inc plan to announce a $53 billion merger as soon as Friday morning, two people said on Thursday. Dublin- based Shire, which sells drugs for rare diseases, said earlier this week it was ready to recommend a deal to shareholders after AbbVie increased its offer.

  • Midday Glance: Pharmaceuticals companies Wednesday, 16 Jul 2014 | 2:54 PM ET

    Baxter International Inc. fell$. 23 or. 3 percent, to $76.53. Bristol-Myers Squibb Co. fell$. 08 or. 2 percent, to $48.63. Hospira fell$. 17 or. 3 percent, to $50.58.